Adopting #coffeetraceability blockchain technology, ALKO buyers can now trace the journey of coffee from farm to cup.
JAMBI, Indonesia, Feb. 26, 2021 /PRNewswire/ -- In the Virtual Indonesian Coffee Promotion 2021 for China market held by the Ministry of Foreign Affairs of the Republic of
ALKO was established to provide assistances to coffee farmers to increase their production capacity as the main income. Currently ALKO develops more than 600 Arabica coffee farmers from 24 villages all over Mount Kerinci.
Collaborating with a global blockchain company, EMURGO, ALKO has developed coffee traceability technology that can trace coffee journey from harvesting in the fields, roasting, to serving in cafes. This technology has been implemented in local roasters / cafes such as Noka Coffee, Khasta, and Blue Korintji, as well as international buyers from France, Japan and Malaysia for almost a year now.
According to Suryono, in addition to a better customer experience, in the upstream blockchain is crucial for farmers in maintaining the quality of their coffee beans. "With more than 600 farmers that we empower, if there are buyers who are not satisfied with the quality of the product, now we can immediately find the root of the problem and make improvements both with farmers and roasters. Blockchain is very helpful in increasing productivity and maintaining the quality of coffee beans," said Suryono.
The taste of Indonesian coffee is known to be one of the best in the world. As the world's 4th largest coffee producer, in the past decade, the Indonesian coffee industry has initiated various improvements on business practices. In 2019, Indonesia's coffee export value has achieved more than US$ 833 Million.
Indonesia and China are strategic and comprehensive partners and China is one of the potential markets for Indonesian Specialty coffee beside the United States, Germany, and Australia.
"It all started back in 1999, when Starbucks opened their first outlet in Beijing. Since then, China coffee consumption grows 30% per year, way higher compared to the world's, which is only 2% per year. Online sales have greatly boosted penetration of the Specialty coffee market in China," said Djauhari Oratmangun, Indonesian Ambassador to the People's Republic of China and Mongolia, on his keynote speech.
This Virtual Indonesian Coffee Promotion is a part of the Indonesia Coffee Diplomacy Campaign 2020 / 2021 and is a preliminary to the Virtual Business Matching on March 24th, 2021, which will involve the Indonesia's Ministry of Foreign Affairs, Indonesia Specialty coffee business practitioners, INACHAM, and Mainland China Coffee Associations.
- 350 tons annual production capacity of export quality Specialty-grade Arabica Kerinci coffee beans.
- ALKO has achieved the Coffee and Farmer Equity (C.A.F.E.) Practice Certificate and possesses and exclusive rights to supply Specialty Arabica Kerinci beans to the world's larges coffee chains.
- Serving dozens of Roasters in New Zealand, USA, UK, Norwegia, Japan, Malaysia, France, Russia, and United Arab Emirates.
- ALKO Academy Scholarship for the kids of farmers to learn agribusiness in selected Universities.
- ALKO initiated "Trash Bank" program, inviting all Mount Kerinci climbers to trade 1 kilogram of trash they found on the mountaint with 100 grams of coffee beans.
Insilico Medicine Achieves Industry First Nominating Preclinical Candidate for Idiopathic Pulmonary Fibrosis With Both Novel Drug Target and Novel Molecule Discovered by Artificial Intelligence
Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, said:
"The pinnacle of the deep learning revolution can be pinged to 2014 when deep learning systems accelerated by NVIDIA GPUs and AI software started outperforming humans in image recognition and generative adversarial networks were invented. It is also the year when we started the company. In 2016 we demonstrated that a deep learning system can identify a novel biological target from omics data with experimental validation. From 2017 and 2019 we consistently demonstrated that generative AI can invent and design novel molecules that work in human cells and in animals.
But the big question remained —- can AI design a novel molecule for a novel target that has no known inhibitors and has not been validated in a disease? And now we have successfully linked both biology and chemistry and nominated the preclinical candidate for a novel target, with the intention of taking it into human clinical trials, which is orders of magnitude more complex and more risky problem to solve.
To my knowledge this is the first case where AI identified a novel target and designed a preclinical candidate for a very broad disease indication. It is a major milestone for us as our ultimate moonshot is to go after senescence and we need to have many enabling AI technologies that help us understand and manipulate human biology in other chronic diseases."
The company also announced the formation of a team of over 20 expert drug hunters and drug developers in Shanghai led by Dr. Feng Ren, former senior VP of biology and chemistry at Medicilon, and former head of chemistry at GSK, who joined Insilico in February as Chief Science Officer. This team will be responsible for taking the AI-discovered drugs into human clinical trials and creating a broad portfolio of preclinical assets.
Moreover, since Insilico will have the financial resources to go after a limited number of novel targets, the company made its target discovery and generative chemistry systems available to the pharmaceutical and biotechnology companies via its Pharma.AI software suite. PandaOmics target discovery system is available as software as a service and Chemistry42 small molecule generative chemistry platform is available for on-premise deployment since September 2020. So far, the most advanced pharmaceutical companies have started deployments and some deployed Chemistry42. PandaOmics is now used by multiple academic institutions and pharmaceutical companies specializing in novel target discovery.
The preclinical candidate is a first-in-class novel small molecule inhibitor of a novel biological target with unprecedented mechanism of action (MOA). It demonstrated experimentally great in vitro and in vivo efficacy in preclinical studies for idiopathic pulmonary fibrosis, and good safety profile in the 14-day repeated mouse dose range finding study. To nominate a preclinical candidate, Insilico Medicine started with a set of 20 completely novel targets discovered by AI for fibrosis and narrowed down the target to specifically address IPF. Subsequently, Insilico generated a set of novel compounds to selectively inhibit the novel target. The molecules had to be selective, bioavailable, metabolically stable, capable of oral administration, safe, and have many other properties of a good drug. The company also predicted high-probability of success of the phase 2 clinical trial outcome in IPF. The molecules were first generated using Insilico's Chemistry42 system, powered by NVIDIA V100 Tensor Core GPUs, that adopts Structure-based Drug Design (SBDD) generative chemistry approach, tested in human cell and animal models. Subsequently, the molecules were re-designed using the Ligand-based Drug Design (LBDD) to optimize for additional properties, and then tested in human cells and animal models. After a review by a large team of internal and external veteran drug developers specializing in fibrosis, a preclinical candidate was nominated, and IND-enabling experiments started.
From target hypothesis to preclinical candidate selection, Insilico was able to complete target identification, molecule generation and validation through traditional laboratory experiments in less than 18 months and at a total cost of approximately $1,800,000 for IPF and $800,000 for other fibrotic disorders, with less than 80 small molecules synthesized and tested.
Insilico's AI-discovered and validated preclinical candidate for IPF achieves several multiple industry firsts in the fields of biotechnology and drug discovery:
- By proving the effectiveness of AI-imagined novel drug targets and molecules through successful validation with multiple human cell and animal model experiments, today's breakthrough marks the industry's first-ever scientific validation of AI for R&D leading up to preclinical studies.
- Linking chemistry and biology for the first time during drug discovery: Historically the steps involved in designing new drugs and validating their effectiveness through preclinical and clinical studies have been disparate parts of the drug discovery process.
- Insilico has achieved a new record speed and lowest cost for preclinical candidate selection — enabling the dramatic acceleration of preclinical development while drastically decreasing drug development costs by millions of dollars.
"We're rewriting the playbook for drug discovery by being the first mover and leader in creating the first and only AI-powered integrated system for drug discovery," said Dr. Zhavoronkov. "By creating the first universal system linking all of the areas of drug development from target identification, small molecule design, and soon clinical trial outcomes prediction, Insilico's AI platform will be capable of supporting every step of pharmaceutical R&D."
Industry Commentary and Additional Information
"AI is transforming the healthcare industry, enabling breakthroughs that can improve millions of lives. Using NVIDIA's AI platform, Insilico Medicine, a premier NVIDIA Inception member, has done what we only dreamed of a few years ago: applying AI to dramatically accelerate drug discovery. And it is doing so at a time when it's never been more critically important to bring the power of AI to every industry to solve our greatest challenges." — Jensen Huang, CEO and founder of NVIDIA
"One of the most difficult steps and biggest mysteries in drug discovery is related to target validation, specifically identifying the targets that have a strong impact in a clinical setting. Insilico Medicine has managed to tackle one of the biggest mysteries in drug discovery through its AI endeavors." — Dr. Tudor Oprea, Professor and Chief of the Translational Informatics Division at the University of New Mexico and experienced drug-hunter with 25 years industrial and academic experience in drug discovery
"Speed is everything in drug development. At least 90 percent of the costs associated with getting a drug approved for human use is in the late stage clinical trials. With its AI-powered universal system for drug discovery, Insilico is enabling researchers to figure out how to fail faster much earlier during the many phases of the drug discovery process leading up to clinical trials before it gets too late." — Dr. Charles Cantor, Professor Emeritus at Boston University, member of the Science Advisory Board at Insilico Medicine, co-Founder of Sequenom Inc., and co-Founder of Retrotope Inc.
"This achievement of Insilico Medicine is another piece of evidence that AI is a powerful tool for drug discovery. By using AI in as many steps of the process as possible, AI can significantly reduce the time and cost to developing effective therapies." — Dr. Alán Aspuru-Guzik, Professor of Chemistry and Computer Science at the University of Toronto, and co-founder of AI companies Kebotix and Zapata Computing
About Insilico Medicine
Insilico Medicine develops software that leverages generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trials outcomes. The company integrates two business models; providing AI-powered drug discovery services and software through its Pharma.AI platform (www.insilico.com/platform/) and developing its own pipeline of preclinical programs. The preclinical program is the result of pursuing novel drug targets and novel molecules discovered through its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million and received multiple industry awards. Insilico Medicine has also published over 100 peer-reviewed papers and has applied for over 25 patents. Website http://insilico.com/
Related Links :
The world's first AI-powered oracle platform, Oraichain, set to combine AI with Blockchain services to introduce a new generation of smart, secure and interoperable smart contracts.
- Oraichain aims to tackle bottlenecks in traditional oracle systems by making AI API's scalable, interoperable, accurate and secure.
- The platform will be easy to use and scalable through bridges to the most popular Blockchain networks.
- The new interconnected ecosystems set to accelerate Web3, DeFi, enterprise and academia applications.
SINGAPORE, Feb. 24, 2021 /PRNewswire/ -- Oraichain, a leading AI-powered oracle and blockchain ecosystem supplier, announced it is to expand into the Artificial Intelligence services industry with a new, AI-backed blockchain network.
The expansion is a new milestone on Oraichain's journey to becoming an advanced, full-service AI ecosystem with the ability to custom create multiple applications and platforms based upon a trusted, transparent and secure blockchain for numerous industry sectors.
The new move to launch its blockchain network referred to as Oraichain Mainnet, adds to Oraichain's plans to expand its suite of AI-based products and services ecosystem, including an AI Marketplace, Data & Request Hub, Publisher Service, Training Service, and Dapp Hosting.
Commenting on the move, Dr Chung Dao, CEO, Oraichain Pte. Ltd., said: "Blockchain technology can disrupt traditional sectors suffering decades of inertia. But it needs a boost. We want to push the limits of innovation by being the first to combine Artificial Intelligence and Blockchain to end the stalemate and create new paradigms in day-to-day service interaction".
According to Reportlinker, the global blockchain market size is expected to grow from USD 3.0 billion in 2020 to USD 39.7 billion by 2025, at a Compound Annual Growth Rate (CAGR) of 67.3%. However, traditional blockchain oracles have reached a bottleneck due to an inability to access data and APIs in a scalable, interoperable, accurate and secure manner - This is where AI can add value.
Boosting Blockchain with AI
Introducing AI to the Blockchain arena provides exponential improvements in data processing. By introducing its blockchain network in partnership with its AI ecosystem, Oraichain delivers the unique infrastructure for AI services and consensus mechanisms for Blockchain services and AI training.
The distinctive use of AI APIs also allows Oraichain to process and create data on-the-fly via virtual machines on smart contracts, a step-up from the primary function of traditional Blockchain oracles that purely connect real-world data to store securely.
The introduction of AI allows for the upgrade of blockchain platforms by improving data quality, reliability and security through enhanced test cases on the Oraichain network, avoiding intermediaries.
By doing so, Oraichain can increase trust and open up unprecedented application functionalities, boosting blockchain and paving the way for a new generation of smart contracts and accelerating Web3, DeFi, and enterprise development applications. Some examples of applications being developed by Oraichain include:
- yAI.finance, the first use case of Oraichain, a platform in the decentralized finance space using unique AI-based features.
- Oraichain AI Marketplace, which will provide access to AI products and APIs aiming to become the one-stop-shop for Artificial Intelligence services.
- aiRight, a patent-pending AI-generated copyright system.
The key to expanding the Oraichain network will be interoperability, a standout feature of Oraichain's roadmap. Once developed, Oraichain will allow for easy and scalable platform adoption through bridges to the most popular Blockchain networks, allowing Oraichain to support more decentralized applications.
Oraichain has already worked with multiple industry leaders on real-world use cases, including leading Vietnam-based IT software firm, Rikkeisoft and KardiaChain, a public blockchain and AI virtual assistant development platform, Vaiot.
For case studies and more information on Oraichain's unique partnerships and development projects, please visit Oraichain website.
Oraichain is an AI-Powered Oracle and Blockchain Ecosystem. Oraichain data oracle platform aggregates and connects Artificial Intelligence APIs to smart contracts and regular applications. Founded by Dr Chung Dao, Oraichain's mission is to be the portal between AI and blockchain technologies, aiming to revolutionize the AI, DeFi, and Blockchain industries.